Intro

This chapter explores the FDA's recent approval of Cabenphi, an antipsychotic with a unique mechanism that moves beyond traditional dopamine antagonists. It also recounts personal experiences during a tumultuous conference impacted by Hurricane Helene, while delving into the scientific background of its key component, xanomaline.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.